Unheard voices: Outcomes of tertiary care for treatment-refractory psychosis

BJPsych Bulletin

Volumn 38, Issue 2, 2014, Pages 71-74

  Sarkar, S Neil ^a,b   Tracy, Derek K ^b,c   Fernandez, Maria Jesus Mateos ^b   Nalesnik, Natasza ^b   Dhillon, Gurbinder ^c   Onwumere, Juliana ^d   Prins, Anne Marye ^d   Schepman, Karen ^b   Collier, Tracy ^b   White, Thomas P ^b   Patel, Anita ^b   Gaughran, Fiona ^d   Shergill, Sukhwinder S ^b,d  

^a CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BEHAVIOR CHANGE; COGNITIVE THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE INCREASE; FAMILY THERAPY; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERCEPTION DISORDER; PERSONAL APPEARANCE; PSYCHOSIS; REFRACTORY PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SECONDARY HEALTH CARE; TERTIARY HEALTH CARE; THOUGHT DISORDER; ACCOMMODATION; ADOLESCENT; CLINICAL OUTCOME; COST BENEFIT ANALYSIS; ICD-10; MONOTHERAPY; PSYCHIATRIC INTENSIVE CARE UNIT; VOICE;

EID: 84973466149     PISSN: 20564694     EISSN: 20564708     Source Type: Journal    
DOI: 10.1192/pb.bp.112.042598     Document Type: Article

References (24)

1. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-78.
2. Tracy DK, Sendt KV, Shergill SS. Antipsychotic polypharmacy: still dirty, but hardly a secret. A systematic review and clinical guide. Curr Psychopharmacol 2013; 2: 91-130.
3. Sendt KV, Giaroli G, Tracy DK. Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol 2012; article id 427267.
4. Papanastasiou E, Stone JM, Shergill S. When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 2013; 202: 91-3.
5. Barnes TR Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620.
6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161 (Suppl. 2): 1-56.
7. Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines. Wiley-Blackwell, 2012.
8. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-5.
9. NHS Specialised Services. Definition no. 22 Specialised mental health services (all ages). In Specialised Services National Definitions Set (3rd edn). NHS Specialised Services, 2009.
10. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-70.
11. Patel A, Everitt B, Knapp M, Reeder C, Grant D, Ecker C, et al. Schizophrenia patients with cognitive deficits: factors associated with costs. Schizophr Bull 2006; 32: 776-85.
12. Nirodi P, Mitchell AJ, Mindham RHS Survey of expert second opinions in a tertiary psychiatric out-patient clinic in the Yorkshire region between 1988 and 2000. Psychiatr Bull 2003; 27: 416-20.
13. Ker S, Anderson I. Service innovations: developing a specialised (tertiary) service for the treatment of affective disorders. Psychiatr Bull 2006; 30: 103-5.
14. Shepherd DJ, Insole LJ, McAllister-Williams RH, Ferrier IN. Are specialised affective disorder services useful? Psychiatr Bull 2009; 33: 41-3.
15. Mihalopoulos C, McGorry P, Roberts S, McFarlane C. The procedural validity of retrospective case note diagnosis. Aust N Z J Psychiatry 2000; 34: 154-9.
16. Michalopoulou PG, Azim A, Tracy D, Shergill SS. Ropinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia: a case report. J Clin Psychopharmacol 2012; 32: 719-20.
17. Patel SS, Attard A, Jacobsen P, Shergill S. Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. BMC Psychiatry 2010; 10: 69.
18. Patel SS, Attard A, Jacobsen P, Shergill S. Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report. BMC Psychiatry 2010; 10: 68.
19. Gromann PM, Tracy DK, Giampietro V, Brammer MJ, Krabbendam L, Shergill SS. Examining frontotemporal connectivity and rTMS in healthy controls: implications for auditory hallucinations in schizophrenia. Neuropsychology 2012; 26: 127-32.
20. Simons CJ, Tracy DK, Sanghera KK, O'Daly O, Gileen J, Domingues MD, et al. Functional magnetic resonance imaging of inner speech in schizophrenia. Biol Psychiatry 2010; 67: 232-7.
21. Tracy DK, O'Daly O, Joyce DW, Michalopoulou PG, Basit BB, Dhillon G, et al. An evoked auditory response fMRI study of the effects of rTMS on putative AVH pathways in healthy volunteers. Neuropsychologia 2010; 48: 270-7.
22. Craddock N, O'Donovan MC, Owen MJ. Phenotypic and genetic complexity of psychosis. Invited commentary on⋯ Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 2007; 190: 200-3.
23. Falkenburg J, Tracy DK. Sex and schizophrenia: a review of gender differences. Psychosis 2012; http://www.tandfonline.com/doi/full/10.1080/17522439.2012.733405, accessed July 2013.
24. Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011; 198: 173-5.